-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ADX-097 in Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ADX-097 in Inflammation report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ADX-097 in Inflammation Drug Details: ADX-097 is under development for the treatment of...
-
Product Insights
Traumatic Spinal Cord Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Traumatic Spinal Cord Injury - Drugs In Development, 2023’, provides an overview of the Traumatic Spinal Cord Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Traumatic Spinal Cord Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Alopecia Areata – Drugs In Development, 2023
Global Markets Direct’s, ‘Alopecia Areata - Drugs In Development, 2023’, provides an overview of the Alopecia Areata pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alopecia Areata, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Alopecia – Drugs In Development, 2023
Global Markets Direct’s, ‘Alopecia - Drugs In Development, 2023’, provides an overview of the Alopecia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Spinal Cord Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Spinal Cord Injury - Drugs In Development, 2023’, provides an overview of the Spinal Cord Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Spinal Cord Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bempikibart in Alopecia Areata
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bempikibart in Alopecia Areata report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bempikibart in Alopecia Areata Drug Details: bempikibart (ADX-914) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – VAX-014 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VAX-014 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VAX-014 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ADX-097 in Autoimmune Disorders
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ADX-097 in Autoimmune Disorders Drug Details: ADX-097 is under development for the treatment of severe...
-
Product Insights
Ischemic Stroke – Drugs In Development, 2023
Global Markets Direct’s, ‘Ischemic Stroke - Drugs In Development, 2023’, provides an overview of the Ischemic Stroke pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...